Viewing nowCombinationPINKAB Tabletten 30/2.5 mg (Pimasartan Potassium, Es-Amlodipine)
Fimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.

MFDS item code 202300088 · Approved 2023.01.06 · Insurance code 628902180
Treatment of essential hypertension not adequately controlled with fimasartan monotherapy
Pimasartan potassium is a medication primarily used when adequate blood pressure control is not achieved with monotherapy in patients with essential hypertension. This medication helps reduce blood pressure by dilating blood vessels, thus providing more effective blood pressure control. Therefore, Pimasartan potassium can assist in cases where blood pressure control is difficult due to essential hypertension.
The recommended dose of this medicine is 1 tablet once daily, taken with water, regardless of meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using fimasartan. However, if blood pressure is not controlled as described below, a direct switch to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is necessary in elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with this medicine containing fimasartan 30 mg. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This drug should not be given to patients with allergies to its active ingredients or similar substances, those who are pregnant or nursing, patients undergoing dialysis, patients with moderate to severe liver dysfunction, patients with biliary obstruction, and certain kidney diseases or diabetes. Caution is warranted in patients with low blood volume or salt depletion, those with impaired kidney function, patients with renovascular hypertension, certain heart disease patients, elderly patients, and those with allergies to specific pigments. This medication may cause side effects such as dizziness, headaches, facial swelling, urination disorders, insomnia, and flushing; if such symptoms occur, consultation with a healthcare provider is necessary. Patients with low blood pressure or electrolyte imbalances should be particularly cautious, as there is a risk of excessively low blood pressure or elevated potassium levels; regular monitoring is needed. This medication may interact with other antihypertensive medications, diuretics, potassium-sparing diuretics, certain antibiotics, antifungals, and lithium preparations, so patients must inform their healthcare providers of any medications they are taking. Pregnant or nursing women are advised not to take this medication, and should consult with a physician about alternative medications if necessary. Its safety and efficacy have not been established for children under 18 years of age, so it is recommended not to use it in this population. In case of overdose, symptoms such as low blood pressure and heart rhythm abnormalities may occur, so patients should contact a medical institution immediately for appropriate treatment. This medication should be kept out of reach of children, and it is important not to transfer it to another container to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a special container that prevents light exposure. It is also safe to store it at room temperature between 1 and 30 degrees Celsius.
White, film-coated tablets with rounded edges in a square shape
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.